Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its another program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.